Imaging Targeted Therapy Response and Resistance in Glioblastoma

Glioblastoma (GBM) is the most common and most malignant tumour of the central nervous system. Despite recent advances in understanding the biology of GBM, the disease still remains in desperate need of effective treatment options resulting in long-term improvements in overall patient survival. Molecularly targeted therapies, anti-angiogenic therapy and immunotherapy are promising avenues under investigation as future therapeutic options. Molecular imaging (MI) is an essential tool in the development of these targeted treatments, both preclinically and clinically. MI facilitates the preclinical study and interrogation of potential therapies. MI further supports non-invasive, longitudinal monitoring of therapy response and allows the study of emergence of treatment resistance via an imaging-guided therapeutic approach.